Your browser doesn't support javascript.
loading
Prognosis of impulse control disorders in Parkinson's disease: a prospective controlled study.
Wirth, Thomas; Goetsch, Thibaut; Corvol, Jean-Christophe; Roze, Emmanuel; Mariani, Louise-Laure; Vidailhet, Marie; Grabli, David; Mallet, Luc; Pelissolo, Antoine; Rascol, Olivier; Brefel-Courbon, Christine; Ory-Magne, Fabienne; Arbus, Christophe; Bekadar, Samir; Krystkowiak, Pierre; Marques, Ana; Llorca, Michel; Krack, Paul; Castrioto, Anna; Fraix, Valérie; Maltete, David; Defebvre, Luc; Kreisler, Alexandre; Houeto, Jean-Luc; Tranchant, Christine; Meyer, Nicolas; Anheim, Mathieu.
Affiliation
  • Wirth T; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, 67098, Strasbourg, France. thomas.wirth@etu.unistra.fr.
  • Goetsch T; Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch-Graffenstaden, France. thomas.wirth@etu.unistra.fr.
  • Corvol JC; Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France. thomas.wirth@etu.unistra.fr.
  • Roze E; Service de santé Publique, GMRC, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Mariani LL; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Vidailhet M; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Grabli D; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Mallet L; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Pelissolo A; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Rascol O; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Brefel-Courbon C; Department of Mental Health and Psychiatry, University of Geneva, Geneva, Switzerland.
  • Ory-Magne F; INSERM U955, Laboratoire Neuro-Psychiatrie Translationnelle, Créteil, France.
  • Arbus C; AP-HP, DMU IMPACT, Service de Psychiatrie, Hôpitaux Universitaires Henri-Mondor, Créteil, France.
  • Bekadar S; Service de neurologie B8, CHU Toulouse, Toulouse, France.
  • Krystkowiak P; Centre d'investigations Clinique, CHU Toulouse, Toulouse, France.
  • Marques A; Service de neurologie B8, CHU Toulouse, Toulouse, France.
  • Llorca M; Service de neurologie B8, CHU Toulouse, Toulouse, France.
  • Krack P; Pôle de psychiatrie, Universitaire, CHU de Toulouse, Université Paul Sabatier Toulouse, Toulouse, France.
  • Castrioto A; Assistance Publique Hôpitaux de Paris, Paris Brain Institute-ICM, Inserm, CNRS, Departement de neurology, Clinical Investigation Center for neurosciences, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Fraix V; Service de Neurologie, Centre Hospitalo-Universitaire d'Amiens, Amiens, France.
  • Maltete D; CHU, CNRS, Clermont Auvergne INP, Institut Pascal, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Defebvre L; Service de Psychiatrie, Centre Hospitalo-universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
  • Kreisler A; Department of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Houeto JL; Neurology Department, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, University Grenoble Alpes, 38000, Grenoble, France.
  • Tranchant C; Neurology Department, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, University Grenoble Alpes, 38000, Grenoble, France.
  • Meyer N; Service de Neurologie, Centre Hospitalier Universitaire, Rouen, France.
  • Anheim M; Neurologie and Pathologie du Mouvement, CHU de Lille, Lille, France.
J Neurol ; 271(5): 2412-2422, 2024 May.
Article in En | MEDLINE | ID: mdl-38214756
ABSTRACT

BACKGROUND:

The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson's disease (PD).

OBJECTIVE:

Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments. MATERIALS AND

METHODS:

We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up. ICD were assessed using the Ardouin's Scale of Behaviors in PD (ASBPD), cognition using the Mattis scale, and PD symptoms using the UPDRS score. Treatment adjustments, DA withdrawal-associated symptoms, and ICDs social consequences were recorded.

RESULTS:

149 patients were included (78 cases and 71 controls), mean duration of follow-up was 4.4 ± 1 years. At baseline, psychiatric disorders were more common among BL-ICD + (42.3 vs 12.3% among BL-ICD-, p < 0.01). At follow-up, 53.8% of BL-ICD + were not ICD-free while 21.1% of BL-ICD- had developed ICD. BL-ICD + more frequently experienced akinesia (21.8 vs 8.5%, p = 0.043) and rigidity worsening (11.5 vs 1.4%, p = 0.019) following therapeutic modifications. Decision to decrease > 50% DA doses (12.8 vs 1.4%, p = 0.019) or to withdraw DA (19.2 vs 5.6%, p = 0.025) was more frequently considered among BL-ICD+ . At follow-up, the prevalence of cognitive decline was lower among BL-ICD + (19.2 vs 37.1%, p = 0.025).

CONCLUSION:

ICDs were associated with increased psychiatric burden at baseline and better cognitive prognosis. Most patients were still showing ICDs at the follow-up visit, suggesting ICD to be considered as a chronic, neuropsychiatric disorder.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Disruptive, Impulse Control, and Conduct Disorders Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurol Year: 2024 Document type: Article Affiliation country: Publication country: ALEMANHA / ALEMANIA / DE / DEUSTCHLAND / GERMANY

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Disruptive, Impulse Control, and Conduct Disorders Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurol Year: 2024 Document type: Article Affiliation country: Publication country: ALEMANHA / ALEMANIA / DE / DEUSTCHLAND / GERMANY